Molecular targeting of renal cell carcinoma by an oral combination

The 5-year survival rate of patients with metastatic renal cell carcinoma (mRCC) is <12% due to treatment failure. Therapeutic strategies that overcome resistance to modestly effective drugs for mRCC, such as sorafenib (SF), could improve outcome in mRCC patients. SF is terminally biotransformed...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncogenesis
Main Authors: Jordan, Andre R., Wang, Jiaojiao, Yates, Travis J., Hasanali, Sarrah L., Lokeshwar, Soum D., Morera, Daley S., Shamaladevi, Nagarajarao, Li, Charles S., Klaassen, Zachary, Terris, Martha K., Thangaraju, Muthusamy, Singh, Amar B., Soloway, Mark S., Lokeshwar, Vinata B.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237463/
https://ncbi.nlm.nih.gov/pubmed/32427869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41389-020-0233-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares